Capstone Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Capstone Asset Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$883K	Sell	20,490 -1,040	-5%	-$37K	0.02%	632
2017 Q1	$674K	Sell	21,530 -1,510	-7%	-$40.5K	0.02%	741
2016 Q4	$582K	Sell	23,040 -9,040	-28%	-$202K	0.02%	834
2016 Q3	$793K	Buy	32,080 +3,060	+11%	+$69.3K	0.02%	684
2016 Q2	$591K	Buy	29,020 +5,940	+26%	+$105K	0.02%	821
2016 Q1	$352K	Buy	23,080 +320	+1%	+$4.17K	0.01%	1154
2015 Q4	$306K	Buy	22,760 +1,990	+10%	+$30.8K	0.01%	1254
2015 Q3	$291K	Buy	20,770 +2,240	+12%	+$41.7K	0.01%	1261
2015 Q2	$315K	Buy	+18,530	New	+$264K	0.01%	1270

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RCAMU

Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

Capstone Asset Management's SUPN Position: Q2 2017 in Review

Capstone Asset Management reduced its Supernus Pharmaceuticals (SUPN) stake by 4.8% in Q2 2017, selling an estimated $37K and leaving 20,490 shares worth $883K. The position accounts for 0.02% of the portfolio, ranked #632.

Capstone Asset Management first reported a position in SUPN in Q2 2015 and has held it in 9 quarters since. 265 funds tracked by Wall St. Rank hold SUPN as of Q2 2017.

Capstone Asset Management held 20,490 shares of Supernus Pharmaceuticals worth $883K as of Q2 2017.
Capstone Asset Management sold 1,040 Supernus Pharmaceuticals shares in Q2 2017, an estimated $37K.
Supernus Pharmaceuticals made up 0.02% of Capstone Asset Management's portfolio in Q2 2017, its #632 holding.
Capstone Asset Management first reported a position in Supernus Pharmaceuticals in Q2 2015 and has held it in 9 quarters since.
265 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2017.

Based on Capstone Asset Management's 13F filing for Q2 2017, filed 10 Jul 2017.